When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

According to Wegovy’s manufacturer, the drug could cost as little as $0 with insurance, or up to $650 for a 28-day supply without insurance. Your cost may vary depending on other factors ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

Lilly achieved the supply milestone first ... had been in shortage—the 0.25-mg starter dose of its obesity GLP-1 Wegovy—as available in late October. At the time, the company said it was ...

Semaglutide, the active ingredient in Ozempic and Wegovy, was also included on the list. The FDA is prioritizing the review ...

the chemical name for Wegovy, and said the agency should consider their role in alleviating the obesity drug supply crunch. Another industry group that represents larger compounding pharmacies ...

Novo Nordisk said it had been able to ease some of the restrictions on the supply of starting doses of Wegovy, starting with the US, that were introduced to try to cope with the massive demand for ...